Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mingfeng Yu

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
Molecular Oncology|August 10, 2019
Targeting CDK9 for treatment of colorectal cancerMuhammed H Rahaman, Frankie Lam, Longjin Zhong, et al.
European Journal of Medicinal Chemistry|September 27, 2015
An integrated approach for discovery of highly potent and selective Mnk inhibitors: Screening, synthesis and SAR analysisTheodosia Teo, Yuchao Yang, Mingfeng Yu, et al.
Journal of Medicinal Chemistry|February 4, 2017
Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and EvaluationSolomon Tadesse, Mingfeng Yu, Laychiluh B Mekonnen, et al.
Gynecologic Oncology|September 22, 2020
A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancerLaychiluh Bantie, Solomon Tadesse, Jimma Likisa, et al.
Gynecologic Oncology|August 3, 2021
Erratum to "A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer" [Gynecologic Oncology 159 (2020) 827-838]Laychiluh Bantie, Solomon Tadesse, Jimma Likisa, et al.
Medicinal Chemistry (Shariqah (United Arab Emirates))|December 21, 2018
Discovery of N-Phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine Derivatives as Potent Mnk2 Inhibitors: Design, Synthesis, SAR Analysis, and Evaluation of in vitro Anti-leukaemic ActivityAhmed M Abdelaziz, Sarah Diab, Saiful Islam, et al.
European Journal of Medicinal Chemistry|September 2, 2017
Dual Inhibition of Mnk2 and FLT3 for potential treatment of acute myeloid leukaemiaSarah Diab, Ahmad M Abdelaziz, Peng Li, et al.
European Journal of Medicinal Chemistry|February 11, 2021
Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluationMingfeng Yu, Theodosia Teo, Yuchao Yang, et al.
Journal of Medicinal Chemistry|January 30, 2014
Discovery of (E)-3-((styrylsulfonyl)methyl)pyridine and (E)-2-((styrylsulfonyl)methyl)pyridine derivatives as anticancer agents: synthesis, structure-activity relationships, and biological activitiesTiangong Lu, Aik Wye Goh, Mingfeng Yu, et al.
Journal of Hematology & Oncology|October 1, 2022
Circulating tumor DNA integrating tissue clonality detects minimal residual disease in resectable non-small-cell lung cancerSiwei Wang, Ming Li, Jingyuan Zhang, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Molecular Oncology|August 10, 2019
Targeting CDK9 for treatment of colorectal cancerMuhammed H Rahaman, Frankie Lam, Longjin Zhong, et al.
European Journal of Medicinal Chemistry|September 27, 2015
An integrated approach for discovery of highly potent and selective Mnk inhibitors: Screening, synthesis and SAR analysisTheodosia Teo, Yuchao Yang, Mingfeng Yu, et al.
Journal of Medicinal Chemistry|February 4, 2017
Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and EvaluationSolomon Tadesse, Mingfeng Yu, Laychiluh B Mekonnen, et al.
Gynecologic Oncology|September 22, 2020
A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancerLaychiluh Bantie, Solomon Tadesse, Jimma Likisa, et al.
Gynecologic Oncology|August 3, 2021
Erratum to "A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer" [Gynecologic Oncology 159 (2020) 827-838]Laychiluh Bantie, Solomon Tadesse, Jimma Likisa, et al.
Medicinal Chemistry (Shariqah (United Arab Emirates))|December 21, 2018
Discovery of N-Phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine Derivatives as Potent Mnk2 Inhibitors: Design, Synthesis, SAR Analysis, and Evaluation of in vitro Anti-leukaemic ActivityAhmed M Abdelaziz, Sarah Diab, Saiful Islam, et al.
European Journal of Medicinal Chemistry|September 2, 2017
Dual Inhibition of Mnk2 and FLT3 for potential treatment of acute myeloid leukaemiaSarah Diab, Ahmad M Abdelaziz, Peng Li, et al.
European Journal of Medicinal Chemistry|February 11, 2021
Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluationMingfeng Yu, Theodosia Teo, Yuchao Yang, et al.
Journal of Medicinal Chemistry|January 30, 2014
Discovery of (E)-3-((styrylsulfonyl)methyl)pyridine and (E)-2-((styrylsulfonyl)methyl)pyridine derivatives as anticancer agents: synthesis, structure-activity relationships, and biological activitiesTiangong Lu, Aik Wye Goh, Mingfeng Yu, et al.
Journal of Hematology & Oncology|October 1, 2022
Circulating tumor DNA integrating tissue clonality detects minimal residual disease in resectable non-small-cell lung cancerSiwei Wang, Ming Li, Jingyuan Zhang, et al.
Pageof 6